Trial reportSleep & breathing = Schlaf & Atmung2025
Dextrose prolotherapy versus low level laser therapy in the treatment of patients with obstructive sleep apnea syndrome; a randomized controlled trial.
Trial report in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06427161 (Dextrose Prolotherapy Versus Low Level Laser Therapy in Treatment of Patients With Obstructive Sleep Apnea Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dextrose Prolotherapy Versus Low Level Laser Therapy in Treatment of Patients With Obstructive Sleep Apnea Syndrome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the effects of Low-level laser therapy (LLLT) versus dextrose prolotherapy injection in the treatment of patients with obstructive sleep apnea (OSA).
methodsA hospital-based randomized controlled trial was conducted among 26 OSA patients; 13 in each group. After confirmation with Polysomnography and evaluation by drug induced sleep endoscopy, the patients were randomly allocated to treatment groups. Treatment success was defined as > 50% reduction of apnea-hypopnea index (AHI) with residual AHI < 10. The outcomes were evaluated 3 months after the intervention.
resultsA total of 26 patients completed the study. The average age was 40.1 ± 7.3 years and 73.1% of the participants were males. Compared with LLLT group before intervention, prolotherapy group had higher reduction of sleep apnea measurements including total apnea, total hypopnea, and low O2 saturation but had slightly lower reduction of average O2 saturation and significant increase in minimal O2 saturation. In both groups, the levels of AHI were significantly reduced after intervention without complication (68% reduction, p = 0.001 in the prolotherapy group and 46% reduction, p = 0.001 in LLLT group). In linear models, the reduction was higher in prolotherapy group even after adjusting to baseline AHI (p = 0.011). Treatment success was much higher in the prolotherapy group than LLLT group (53.8% versus 7.7%, p = 0.030). The treatment success was significantly associated with single level obstruction (velum) and partial obstruction.
conclusionsBoth dextrose prolotherapy and LLLT were successful in reducing sleep parameters associated with OSA, with better reduction in the prolotherapy group. The promising findings need to be confirmed in larger multicenter studies before final recommendation.
trial registrationThe study was listed on www. CLINICALTRIALS: gov with registration number (NCT06427161) on 23/05/2024.
Indexed as
Identifiers
40794160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.